Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathology

*Darren M. Weber,[1]*Matthew A. Stroh, [1] Steven W. Taylor,[1] Robert J. Lagier,[1] Judy Z. Louie,[1] Nigel J. Clarke,[1] David E. Vaillancourt,[2] Sruti Rayaprolu,[2] Ranjan Duara,[2,3] Michael K. Racke[1]

[1] Quest Diagnostics Nichols Institute, San Juan Capistrano, CA

[2] Department of Applied Physiology and Kinesiology, Fixel Institute for Neurological Disorders, and 1Florida ADRC, University of Florida, Gainesville FL

[3] Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, FL

[4] Department of Neurology, Center for Translational Research in Neurodegenerative Disease, 1Florida ADRC, University of Florida, Gainesville, FL

[5] Department of Pharmacology and Chemical Biology and Department of Neurology Center for Neurodegenerative Disease, Goizueta Institute Emory Brain Health, Emory University, School of Medicine. Atlanta, GA

* These authors contributed equally to this work and share first authorship

Corresponding Author:

Darren Weber

darren.m.weber@questdiagnostics.com

1-949-728-4668

Quest Diagnostics Nichols Institute

33608 Ortega Hwy, B207

San Juan Capistrano, CA 92675

Word count: 4,471 [4,500 max]

ABSTRACT

Background and Objectives: Plasma biomarkers provide new tools to evaluate patients with mild cognitive impairment (MCI) for Alzheimer's disease (AD) pathology. Such tools are needed for anti-amyloid therapies that require efficient and accurate diagnostic evaluation to identify potential treatment candidates. This study sought to develop and evaluate the clinical performance of a multi-marker combination of plasma beta-amyloid 42/40 (Aβ42/40), ptau-217, and *APOE* genotype to predict amyloid PET positivity in a diverse cohort of patients at a memory clinic and evaluate >4,000 results from "real-world" specimens submitted for high-throughput clinical testing.

Methods: Study participants were from the 1Florida AD Research Center (ADRC). Demographics, clinical evaluations, and amyloid PET scan data were provided with plasma specimens for model development for the intended-use cohort (MCI/AD: n=215). Aβ42/40 and ApoE4 proteotype (reflecting high-risk *APOE* ε4 alleles) were measured by mass spectrometry and ptau-217 by immunoassay. A likelihood score model was determined for each biomarker separately and in combination. Model performance was optimized using 2 cutpoints, 1 for high and 1 for low likelihood of PET positivity, to attain ≥90% specificity and sensitivity. These cutpoints were applied to categorize 4,326 real-world specimens and an expanded cohort stratified by cognitive status (normal cognition [NC], MCI, AD).

Results: For the intended-use cohort (46.0% prevalence of PET-positivity), a combination of Aβ42/40, ptau-217, and *APOE4* allele count provided the best model with a receiver operating characteristic area under the curve (ROC-AUC) of 0.942 and with 2 cutpoints fixed at 91% sensitivity and 91% specificity yielding a high cutpoint with 88% positive predictive value (PPV) and 87% accuracy and a low cutpoint with 91% negative predictive value (NPV) and 85% accuracy. Incorporating *APOE4* allele count also reduced the percentage of patients with indeterminate risk

from 15% to 10%. The cutpoints categorized the real-world clinical specimens as having 42% high, 51% low, and 7% indeterminate likelihood for PET positivity and differentiated between NC, MCI, and AD dementia cognitive status in the expanded cohort.

Discussion: Combining plasma biomarkers Aβ42/40, ptau-217, and *APOE4* allele count is a scalable approach for evaluating patients with MCI for suspected AD pathology.

<u>Key Takeaways:</u>

1.) The approval of disease-modifying therapies for Alzheimer's disease ushers in the need for accessible, affordable, and accurate blood-based testing for Alzheimer's pathology.
2.) Models implementing multiple analytes have demonstrated high performance in identifying patients with brain amyloid pathology.
3.) We developed high-throughput, robust, multiple-analyte assays and models aimed at predicting the likelihood of amyloid PET positivity.
4.) We report two models with excellent performance in alignment with current recommendations for blood-based testing.
5.) Aβ42/40 + ptau-217 + *APOE4* allele count provided the best prediction for amyloid PET positivity when sensitivity and specificity were both fixed at 91%.

1. INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by beta-amyloid (Aβ) plaques and neurofibrillary tangles in the brain that are associated with cognitive impairment.[1] Traditional practice evaluated Alzheimer's disease pathology postmortem, but advancements in the understanding and utilization of biomarkers led to the ability to identify patients with ongoing AD pathological changes and thus identify patients for treatment with approved disease modifying agents and for clinical trials of investigational drugs for AD.

Prior to the development of blood biomarkers, PET imaging [2] or CSF evaluation were the only available approaches to determine levels of Aβ and phosphorylated tau protein[3] (ptau, a marker of neurofibrillary tangles) for diagnosis of AD pathology. However, these methods are perceived as invasive and/or costly. Recently, the United States Food and Drug Administration (FDA) approved the first disease-modifying monoclonal antibody treatments for AD that target specific soluble aggregates of beta-amyloid (Aβ).[4,5] These new therapeutics, which are indicated for individuals with mild cognitive impairment (MCI) or mild AD, require confirmation of amyloid pathology and *APOE* ε4 allele (*APOE4*) carrier status prior to administration. Therefore, scalable diagnostic tests that are accurate, less invasive, and affordable are needed to fulfill this need.[6]

Recent advances in blood-based biomarkers (BBM) provide clinicians with a more cost-effective and accessible means to evaluate these biomarkers.[7] High-throughput mass spectrometry (MS) and immunoassay platforms combined with automated sample preparation provide a scalable approach to measure large numbers of blood specimens with fast turn-around times. Recently, we developed a liquid chromatography-tandem MS (LC-MS/MS) plasma test to evaluate cerebral Aβ pathology using a ratio of peptides beta-amyloid 42 (Aβ42) to beta-amyloid 40

98 (Aβ40) (ie, Aβ42/40) to predict amyloid PET status.[8,9] In addition, plasma tau protein phosphorylated
99 at threonine 217 (ptau-217) is another excellent marker of AD-related neuropathology.[10]

100 The Alzheimer's Association recently included Aβ42 and ptau-217 in their guidelines as
101 BBMs for core AD pathologies and processes.[11] Furthermore, combinations of plasma biomarkers
102 can provide greater accuracy in identifying and differentiating AD dementia from other
103 neurodegenerative disorders.[12-16] Additionally, some studies demonstrated that inclusion of *APOE4*
104 allele carrier status or allele count, which confer elevated risk for AD, can improve model
105 performance when combined with the plasma Aβ42/40 ratio and/or ptau-217,[15,17] while others
106 showed no statistically significant improvement.[8,14]

107 For combinations of plasma biomarkers to have substantial clinical value, they should have
108 acceptable diagnostic performance on par with currently accepted CSF tests.[18] In addition, BBMs
109 should have high test-retest reliability and scalability for high throughput to be considered useful for
110 clinical implementation[19,20] as cost-effective diagnostic tests to identify potential candidates for
111 anti-amyloid therapies.[16,21]

112 In the current study, our objective was to develop a multi-biomarker combination that (1)
113 achieved acceptable performance metrics while maintaining sensitivities and specificities ≥90%
114 using specimens from a well-characterized cohort of patients with MCI and AD; and (2) uses robust
115 high-throughput assays based on accessible cost-effective, low-resolution LC-MS/MS and
116 immunoassay methods.[9,16]

117 We note that these recommendations have been met previously using ptau-217 alone, but
118 in a racially homogeneous (97% white) cohort with a high prevalence (64%) of amyloid positivity[16]
119 and with a model developed using a combination of ptau-217/np-tau217 and Aβ42/40 (94% white
120 and 53% prevalence of amyloid positivity) on a high-resolution MS-based platform.[14]

121 In our cohort, patients were age-, sex-, ethnicity-, and years-of-education matched as PET-
122 negative (n=116) and PET-positive (n=99), representing a lower prevalence (46%) of PET positivity
123 and greater ethnic diversity (54% Hispanic) than prior studies. In addition to using plasma-based
124 Aβ42/40 and ptau-217, we examined the effect of adding *APOE*4 genotype information (ie, carrier or
125 noncarrier vs allele count, ie, 0, 1, or 2 alleles) to the combination of markers. Ultimately, we aim to
126 assess the usefulness of these tests to effectively identify candidates for anti-amyloid therapy.

127

128 **2. METHODS**

129 **2.1 Study Design and clinical evaluation**

130 This cross-sectional study included plasma specimens from 215 participants in the intended-
131 use cohort enrolled with 1Florida Alzheimer's Disease Research Center (ADRC), including 170
132 participants with MCI and 45 participants with AD (**Table 1**). Participants were between the ages of
133 52 and 97 years, had a minimum of a 6th grade reading level, and spoke English and/or Spanish as
134 their primary language. Ethnicity of the participants was self-reported.

135 Participants underwent an extensive neurological and neuropsychological evaluation, including
136 the clinical dementia rating sum of boxes scale (CDRsb),[22] the mini-mental state examination
137 (MMSE),[23] and the Montreal cognitive assessment (MoCA). [24] Diagnoses of normal cognition (NC),
138 MCI and AD dementia were determined using a previously described algorithmic procedure,[25]
139 which combines the neuropsychological diagnosis with the CDRsb scores. Specimens from 56
140 participants with NC were added to the cohort to evaluate the diagnostic performance of the
141 biomarkers for identifying cognitive status (**eTable 1**).
142 In addition, we performed a retrospective analysis of 4,326 consecutive plasma specimens
143 submitted to Quest Diagnostics for plasma Aβ42/40, ptau-217, and ApoE proteoform analysis

144 testing. This was a limited dataset (as defined by https://www.hhs.gov/hipaa/for-
145 professionals/special-topics/research/index.html) with only patient age and sex information
146 available (**eTable 2**).
147
148 **2.2 Amyloid PET imaging**
149 Amyloid PET imaging was carried out using [^{18}F]florbetaben or [^{18}F]florbetapir tracers on a
150 Siemens 16 Biograph PET/CT scanner, as described previously.[26] Global amyloid status (+/-) was
151 determined based on visual read by an experienced rater who was blinded to diagnosis and
152 cognitive status.[26] All participants underwent an amyloid PET scan within 12 months of plasma
153 collection.
154
155 **2.3 Plasma biomarker analysis**
156 Blood specimens were collected by venipuncture into 10-mL tubes containing EDTA as
157 anticoagulant and kept on ice (<1 h) until centrifugation at 1,200 relative centrifuge force for 12 min
158 at room temperature. Plasma aliquots (0.5 mL) were transferred into polypropylene tubes and
159 stored at −80 °C until analysis. All plasma specimens were deidentified, and results were blinded
160 during the analysis.
161
162 **2.3.1 Plasma Aβ42/40 ratio and ApoE proteoform assays**
163 The LC-MS/MS-based assays for the plasma Aβ42/40 ratio and ApoE proteoforms have
164 been described in detail elsewhere.[9] All sample preparation steps were fully automated using a
165 Hamilton Star liquid handler (Hamilton, Reno, NV). LC-MS/MS was performed using a Transcend
166 Vanquish TLX-4 TurboFlow UPLC, with a high-throughput 4-LC column configuration, coupled to a

167 TSQ Altis Plus Triple Quadrupole MS (both Thermo Fisher Scientific, Waltham, MA); data were
168 analyzed using TraceFinder Clinical Research v5.1 software (Thermo Fisher Scientific).

169 For the Aβ42/40 ratio, Aβ40 and Aβ42 were enriched by immunoprecipitation from plasma
170 (0.5 mL) and digested with Lys-C. Characteristic peptides Aβ40 (Aβ29-40) and Aβ42 (Aβ29-42) were
171 desalted, concentrated, chromatographically separated, detected, and quantified by LC-MS/MS.
172 The ratio of the peak area of the analytes to corresponding isotopically labeled internal standards
173 was used to calculate the concentrations from an 8-point standard curve. The ratio of Aβ42 to Aβ40
174 was determined by taking the back-calculated value for Aβ42 and dividing it by the back-calculated
175 value for Aβ40.

176 For ApoE proteoform determination, plasma specimens (25 µL) were reduced, alkylated,
177 and proteolytically digested with trypsin. Post digestion, samples were acidified, centrifuged, and
178 desalted. Unique tryptic peptides to the ApoE2 and ApoE4 proteoforms, as well as shared peptides
179 between the ApoE2 and ApoE3 proteoforms, and the ApoE3 and ApoE4 proteoforms, were
180 chromatographically separated and detected by LC-MS/MS. ApoE proteoforms were determined by
181 the presence or absence of the unique and shared peptides and used to establish ApoE proteotype,
182 which has previously been shown to be 100% concordant with *APOE* genotype.[9]

183 Both assays were validated according to Clinical Laboratory Improvement Amendments
184 (CLIA) guidance. For the Aβ42/40 ratio, assay imprecision (random error) and bias (technical error)
185 was measured previously to establish the technical robustness[8]of the test per Rabe et al.[27] Total
186 error was calculated as described in section 2.4 Statistical analysis.

187

188 **2.3.2 Plasma ptau-217 assay**

189 On the day of the assay, frozen calibrators, quality control samples, and plasma specimens
190 were thawed and brought to room temperature. Plasma specimens were centrifuged to remove any
191 debris, and plasma ptau-217 levels were quantified using the Lumipulse G ptau-217 - Plasma
192 Immunoreaction Cartridges RUO (for research use only) assay kit on a Lumipulse G System
193 (Fujirebio Inc, Malvern, PA), which is a fully automated chemiluminescent enzyme immunoassay
194 (CLEIA) platform.

195 The assay was validated according to CLIA guidance and data were used to evaluate
196 technical robustness per Rabe et al.[27] Inter-assay imprecision (random error) was determined by
197 taking the average of 2 quality control samples (QC) analyzed in duplicate over 14 nonconsecutive
198 days. Bias (technical error) was experimentally determined by analyzing 100 previously assayed
199 plasma specimens using a different lot of reagents. Values for ptau-217 were compared as a
200 percentile difference calculated between the mean values of the original results and retest results,
201 as has been reported elsewhere.[8,27] Total error was calculated as described in the section 2.4
202 Statistical analysis.

203

204 **2.4 Statistical analysis**

205 **2.4.1 Demographic, clinical, and biomarker comparisons**

206 Participant demographics were summarized for the full cohort and further stratified by amyloid
207 PET status. Continuous variables were summarized as mean and standard deviation (SD) or median
208 and interquartile range. Categorical variables were summarized as percent and count (N). Tests for
209 difference between PET status were assessed by two-sample t-test or Wilcoxon Rank-Sum test for
210 continuous variables and Fisher's Exact test for categorical variables. Significance was determined
211 with a threshold of $P \leq .05$.

212 **2.4.2 Logistic regression**

213 Logistic regression modeling was employed to assess the association between predictor
214 variables and amyloid PET status to estimate model linear predictors. The ptau-217 variable as a
215 predictor in the models was natural log transformed.[28] Akaike Information Criterion (AIC) was used
216 to select the final model. Amyloid PET positivity likelihood scores in probability scale were
217 calculated by transforming model linear predictors in natural exponential function. Tests for
218 differences in the distribution of amyloid PET positivity likelihood scores between amyloid PET
219 status were assessed by Wilcoxon Rank-sum test. Model performances of predictors in predicting
220 PET positivity were evaluated by ROC curve analysis. Differences between ROC curves were
221 assessed by the method of DeLong.[29] Comparisons of probability/likelihood scores when stratified
222 by amyloid PET status were conducted using a two-tailed paired t-test.

223 In addition, model performances were also evaluated by a 2-cutpoint approach with the lower
224 cutpoint establishing maximized sensitivity and the upper cutpoint establishing maximized
225 specificity. Recommended performance criteria stipulate that those patients who fall in the
226 indeterminate zone between the two cutpoints represent ≤20% of the population.[18]

227

228 **2.4.3 Technical robustness**

229 To investigate the effects of total error (assay imprecision + potential bias) for the Aβ40, Aβ42,
230 and ptau-217 markers on the predictive performance of the best model, data simulations were
231 performed. Estimates for analytical imprecision and bias were previously established for each
232 marker (data not included). Based on those error estimates, Monte Carlo simulations were
233 performed to generate 10,000 replicate study data sets (N=215) with randomly assigned errors
234 drawn from a Gaussian distribution (mean = 0, %CV = 6%) and fixed bias offsets added to each

biomarker value. Aβ42/40 ratios were generated for each paired set of perturbed amyloid markers. For each simulated data set, observations were scored by the best model (each observation retained its original *APOE4* allele count for scoring) and assigned a new predicted PET+ class (low, indeterminate, or high likelihood) based on the established classification thresholds. Predicted PET+ classes for each simulated data set were tabulated against the original (non-perturbed) data and re-classification rates were estimated. The average (95% CI) re-classification rate due to overall assay error was estimated as the median (2.5th percentile, 97.5th percentile) of the 10,000 simulated reclassification rates.

All data analyses were performed using R version 4.3.1 (The R Foundation for Statistical Computing).

2.5 Data availability

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

2.6 Ethics statement

The studies involving humans were approved by Mount Sinai Medical Center IRB. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired as part of a previous study for which ethical approval was obtained. Written informed consent for participation from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.

3. RESULTS

3.1 Demographic, clinical, and biomarker comparisons

The mean age of participants in the intended-use cohort was 79 years with almost 80% having MCI and the remaining having AD dementia (**Table 1**). Women (56%) were slightly more represented than men and there was a slight majority (54%) of participants with Hispanic ethnicity. Most participants had a CDR score >0 (94%) and an MMSE score ≥25 (nearly 75%, **Table 1**).

Compared to PET-negative participants, PET-positive participants had a significantly higher percentage with a CDR score >0 (P=.040) and significantly lower mean MMSE score (P<.001, **Table 1**). No significant differences between patient age, sex, years-of-education, and ethnicity were found between those who were PET-negative and PET-positive.

Compared to PET-negative participants, PET-positive participants had significantly lower mean levels of plasma Aβ42, higher median levels of ptau-217, and a significantly lower mean Aβ42/40 ratio (P<.001 for all, **Table 1**). No difference in plasma Aβ40 levels between PET-positive and PET-negative groups was observed.

3.2 Prediction of amyloid PET status

As described below, the individual and multi-marker prediction of amyloid PET status using either single or 2-cutpoint approaches were evaluated in terms of optimizing test performance and to meet recommended 90% sensitivity/90% specificity criteria for confirmatory testing.[18] For the2-cutpoint approach, this included keeping the percentage of patients classified as having indeterminate likelihood of PET positivity ≤20%.[18]

3.2.1 Diagnostic performance of individual and combined BBMs for predicting amyloid PET status using a single cutpoint

ROC-AUCs for PET prediction using Aβ42/40 alone (0.851, 95%CI 0.796 to 0.905) and ptau-217 alone (0.846, 95%CI 0.808 to 0.905) significantly improved (*P*<.001) when they were combined (0.929, 95%CI 0.894 to 0.963) (**eTable 3, Figure 1)**. The AIC for the model that combined Aβ42/40 and ptau-217 predictors was 194.6, lower than Aβ42/40 (AIC = 255.6) and ptau-217 (AIC = 262.7) alone (**eTable 3)**. Further improvement on amyloid PET prediction was achieved when *APOE4* results were added to the model, with *APOE4* carrier status (positive/negative) yielding an AUC of 0.938 (95%CI 0.906 to 0.969), and *APOE4* allele count yielding an AUC of 0.942 (95%CI 0.912 to 0.972). However, only the *APOE4* allele count model AUC (AIC = 186.6, *P*=0.033), and not the carrier status model (AIC = 189.2, *P* =0.177), reached statistical significance when compared to the model without *APOE4* results added. Despite high AUCs for each combined BBM predictor, none of the models achieved ≥90% sensitivity/specificity when using a single cutpoint (**eTable 3**, **Figure 1**).

3.2.2 Diagnostic performance of individual and combined BBMs for predicting amyloid PET status using a 2-cutpoint method

At probability cutpoints establishing ≥90% sensitivity and specificity, no individual biomarker met the criterion for ≤20% indeterminate classifications.[18] Aβ42/40 classified 34% and ptau-217 classified 42% of the intended-use population as having an indeterminate result. Combining Aβ42/40 and ptau-217 reduced the indeterminate results to 15%, and further addition of *APOE4* allele count reduced them to 10% (**Figure 2, Table 2**). The reduction represented 21 of 32 participants (66%) being reclassified in the correct direction relative to their PET status (wrong classification to indeterminate [n=6] or indeterminate to correct classification [n=15]). The

302 distribution of results for the intended-use population for the Aβ42/40+ptau-217+*APOE4* allele
303 count model is summarized in **Figure 3A**.

304 The models with vs without *APOE4* allele count with the 2-cutpoints set for 91% sensitivity
305 and 91% specificity at the study prevalence of 46% of PET-positivity were compared. PPVs were
306 88% with *APOE4* allele count and 87% without and NPVs were 91% for both models (**Table 3**). At
307 50% prevalence, which is the prevalence expected in an MCI population,[30] PPV and NPV would both
308 reach 90% for the model with *APOE4* allele count compared to 89% for both PPV and NPV for the
309 model without. At lower prevalence of PET-positivity, such as in a primary care setting where the
310 prevalence would be closer to 20%,[31] the model predictors with and without *APOE4* allele count
311 show a high NPV of 97%. Conversely, at high prevalences of PET-positivity (65%, 80%) the model
312 predictors with and without *APOE4* allele count would have high PPVs (93% to 97%) (**Table 3**).

313

314 **3.3 Stratification by cognitive status**

315 Superimposing probability of PET positivity scores from the *APOE4* allele count model onto
316 cognitive status showed significantly higher probability scores in AD individuals compared to MCI
317 and NC (P<.001 for both), and significantly higher probability scores in MCI individuals vs NC
318 (P=0.002, **eFigure 1A**).

319 ROC-AUCs for independent model predictors for cognitive status were 0.943 (95%CI 0.894
320 to 0.992) for NC vs AD and 0.864 (95%CI 0.817 to 0.911) for MCI vs AD (**eFigure 1B**). However, the
321 model predictor did not perform well by ROC analysis in distinguishing NC from MCI (AUC = 0.650,
322 95%CI 0.568 to 0.740).

323

3.4 Real-world data performance by age

For the 4,326 plasma specimens submitted to Quest Diagnostics for plasma Aβ42/40, ptau-217, and ApoE proteoform testing, the mean age of individuals was 73 years, most (58%) were female, and 38% had 1 or 2 *APOE4* alleles (**eTable 2**). In total, 42% (1,822) were classified as having a high likelihood, 51% (2,204) as having low likelihood, and 7% (300) as having an indeterminate likelihood for PET positivity.

Based on their low likelihood for PET positivity, a PET scan or CSF testing would potentially be unnecessary for the 2,204 patients (**Table 4**). Similarly, imaging or CSF testing may not be required for the 1,822 high-likelihood patients based on the ≥90% sensitivity, specificity, PPV, NPV (**Table 3**) and recent guidance for a projected a prevalence of 50% of PET-positivity.[18]

When parsed by the 3-biomarker model predictor designation that uses *APOE4* allele count, a significant difference in age between the low and high likelihood group (70.3 vs 75.5, ANOVA $P<.001$) and the low and indeterminate likelihood group (70.3 vs 76.3, ANOVA $P<.001$) was observed (**eTable 2**). No differences in age were seen between the indeterminate and high likelihood group.

Further stratifying the results by age, we observed a significant positive relationship between increasing median age and increasing probability of PET positivity (**eFigure 2**). For low likelihood patients, the percentage who are likely PET negative decreases with age, with 90.2% of patients younger than 50 years predicted to be amyloid PET negative compared to 37.2% for those 90 years or older (**eTable 4**).

3.5 Assay technical robustness and effects of bias and imprecision on likelihood reclassification

We evaluated the effects total error, composed of analytical bias (technical error) and imprecision (random error), on likelihood reclassification when using the model predictor with *APOE4* allele count. In the current study, measured bias was -1.1% (95%CI, -3.1% to 0.9%) for ptau-217. Previously measured bias was 12% for Aβ42 and 11% for Aβ40.[8] In the current study, the average measured imprecision for ptau-217, determined by taking the average of 2 QC samples analyzed in duplicate over 14 nonconsecutive days, was 6%. The average imprecision for Aβ42/40, previously measured by taking the average imprecision across 5 study samples analyzed in duplicate over 25 days, was also 6%.[8,9]

Reclassification rates are shown in **eTable 5** and visual representation of classification comparisons with and without total error applied are shown in **eFigure 3**. Median reclassification after total error was applied across 10,000 simulations was 13.5% (9.8% to 16.7%). Within these data, most reclassifications were from indeterminate-to-negative: 3.3% (1.4% to 5.6%) and fewest were from negative-to-positive: 0.9% (0% to 2.3%).

4. DISCUSSION

The need for affordable, scalable, and accessible blood-based testing for Alzheimer's disease has never been more important than with the emergence of the first disease-modifying therapies. We demonstrate that the combination of plasma Aβ42/40, ptau-217, and ApoE proteoform test results, measured using high-throughput LC-MS/MS and immunoassay methods, can predict the likelihood of amyloid pathology using an optimized model and a 2-cutpoint

367 approach (**Table 2**). Automated specimen preparation and analysis allows a 96-well plate to be run
368 in 2 to 8 hours, depending on the assay.

369

370 **4.1 Model performance**

371 The cutpoints were optimized for detecting amyloid PET status in patients with MCI and AD,
372 who represent the intended-use population. In addition, these optimized cutpoints are in alignment
373 with recently published performance recommendations to minimize the number of indeterminate
374 results to ≤20% while maintaining a sensitivity and specificity of ≥90%.[18] This ensures that our test
375 can be used to both rule-in and rule-out amyloid PET positivity consistent with AD pathology as the
376 likely culprit of cognitive impairment. The model minimized the proportion of indeterminate results
377 to ≤10%, thus limiting results that can be uninformative to both patients and clinicians.

378

379 **4.2 Model development**

380 The optimized model was derived from logistic regression combining Aβ42/40, natural log
381 transformed ptau-217 concentrations, and *APOE4* allele count. Each component provided a
382 statistically significant contribution to the risk score, except for the homozygous *APOE4*
383 component. All 12 homozygous *APOE4* individuals in our cohort were PET positive, and the absence
384 of *APOE4* homozygotes in the PET-negative group provided no statistical control.

385 *APOE4* homozygosity has a prevalence of approximately 2% in the general population.[32] We
386 found homozygosity to be slightly higher both in our intended-use cohort and in clinical specimens
387 (about 6%). However, *APOE4* homozygosity combined with PET-negativity would be expected to be
388 extremely rare. For example, Fortea et al found almost 99% of *APOE4* homozygotes had some

389 Alzheimer's disease neuropathologic change.[33] The same study suggested that *APOE4*
390 homozygosity is now being considered a genetically distinct form of Alzheimer's disease.[33]

391 The optimized model was slightly improved over Aβ42/40 combined with ptau-217 in terms
392 of ROC-AUC and had lowest AIC score of all models (**Table 2**). Most importantly, the model
393 substantially reduced of the number of participants with an indeterminate result from 15% to 10%,
394 with about two-thirds of the reclassified participants having a result more predictive of their actual
395 PET status.

396 **4.3 Comparisons with other models**

397 The performance of combinations of biomarkers in predicting amyloid PET status has been
398 reported by several different groups[14-17], including a study by Meyer et al[14] who reported high
399 predictive performance for a high-resolution MS-based assay incorporating ptau-217 normalized to
400 non-phosphorylated tau (% ptau-217, ptau-217/np-tau-217) and Aβ42/40, optimized by a single
401 cutpoint. The combined cohort used to develop the model in this study was less ethnically diverse
402 than ours, although sub cohort analysis indicated that their model had equivalent accuracy
403 regardless of age, sex, race, ethnicity, or *APOE4* status.

404 In contrast to the study by Meyer et al, the design of our study incorporated PET-positive and
405 PET-negative participants, who were age-, sex-, ethnicity-, and years-of-education matched. While
406 they reported on model robustness for subgroups, Meyer et al did not report on assay technical
407 robustness, including the effects of technical and random error on patient classification. Our
408 robustness analysis, which measured total error for both the Aβ42/40 and ptau-217 assays,
409 demonstrated an overall reclassification rate of <14%, and just over 3% for the most risk
410 reclassifications between 2 categories.

411 Other studies showing high performance using fewer biomarkers established PET-positivity
412 using quantitative centiloid (CL) values with cutoffs of >25 CL or >24 CL indicating PET positivity. In
413 contrast, we established PET positivity by central visual read,[10,14,16] which is widely recognized as
414 being highly accurate and the standard to which CL quantification is compared.

415 Recent results from the Amyloid Imaging to Prevent Alzheimer's Disease Diagnostic and
416 Patient Management Study (AMYPAD-DPMS) diagnostic and patient management study
417 demonstrated a 92% agreement between visual read and CL values. However, CL values were
418 considered supportive in only 70% of cases that were considered challenging (11% of scans,
419 expected rate in a memory clinic setting).[34] Results suggest that CL values can be supportive when
420 added to visual read assessment but have not necessarily been shown to be superior to the highly
421 accurate visual read approach, with the authors acknowledging that "quantification should always
422 be done in conjunction with visual assessment to avoid misclassifications due to potential
423 quantification errors." In addition, the authors note the recent adoption of opinion from the
424 Committee for Medicinal Products for Human Use (EMACDOC-17005198181200791) stating that a
425 "threshold of greater than 30 is reflective of established amyloid pathology at the individual level
426 with high certainty."[34]

427 **4.3 Real-world data**

428 Our real-world data set was composed of 4,326 consecutively run Aβ42/40, ptau-217, and
429 ApoE proteoform specimens, submitted by healthcare providers, presumably for suspected
430 dementia due to Alzheimer's disease. As expected, we observed an increase in the likelihood of PET
431 positivity with age, with predicted PET positivity rates ranging from 9% for individuals under the age
432 of 50, to 55% for those 90 or older (**eTable 4**). These results suggest that PPV/NPV could be

433 influenced by age-dependent trends in the prevalence of amyloid PET positivity, particularly for
434 individuals under the age of 70.

435 Using our fixed cutpoints to categorize individuals into low, indeterminate, and high
436 likelihood for amyloid PET positivity, we suggest that results may help guide physicians in clinical
437 decision making (**Table 4**). We note the similarities in the distribution between our intended-use
438 cohort with the clinical specimens across the 3 classifications (**Figure 3**). Projecting the proportion
439 of PET positivity from the intended-use population onto the 4,326 clinical specimens could
440 potentially eliminate the need for PET or CSF testing on 2,204 individuals who are likely to have non-
441 AD etiology, or slightly over 50% of tested individuals. Considering the cost of an amyloid PET scan
442 (~$5,000 USD),[35] removing these individuals alone may potentially save $21,630,000 (less the cost
443 of testing) as well as eliminating travel and wait times to receive imaging services.

444

445 **4.3 Strengths and limitations**

446 Key strengths of this study include its use of scalable, cost-effective plasma biomarkers in a
447 cohort of patients with significant ethnic diversity that is representative of the intended-use
448 population. However, the study was not designed to evaluate the relevance or performance of
449 these markers in the context of other causes of dementia, including mixed dementia with amyloid
450 pathology or early onset Alzheimer's disease or to address the effects of ethnically relevant genetic
451 markers like *APOE4* on predictive performance of the tests. Also, the model will falsely identify PET-
452 negative *APOE4* homozygote individuals as PET-positives, although these individuals are expected
453 to be extremely rare. In our expanded cohort, we found one PET-negative *APOE4* homozygote
454 individual, but they had normal cognition, excluding them from the intended-use population on
455 which the model was built and predictors were trained. Finally, while the model works well for

predicting PET status and differentiated the individuals with different cognitive status, models for predicting cognitive status only work well for differentiating NC from AD.

Replication of these results in other ethnically and socioeconomically diverse groups will support using these biomarkers for clinical assessment of potential candidates for anti-amyloid therapies. Notably, we anticipate diagnostic performance would increase when this information is combined with other clinical and imaging information.[36] Furthermore, combining these results with assessments of cognitive function and imaging to assess for a diversity of neurodegenerative processes will be important in selecting patients who are most likely to respond to specific therapeutic interventions. However, this combination of plasma biomarkers is likely to be able to complement clinical and radiologic diagnostic evaluations to further enhance the accuracy of AD diagnosis.

References

1. Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. *Nat Rev Dis Primers*. 2021;7:33.
2. Chapleau M, Iaccarino L, Soleimani-Meigooni D, et al. The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. *J Nucl Med*. 2022;63:13S-19S.
3. Shaw LM, Arias J, Blennow K, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimers Dement*. 2018;14:1505-1521.
4. van Dyck CH, Sabbagh M, Cohen S. Lecanemab in Early Alzheimer's Disease. Reply. *N Engl J Med*. 2023;388:1631-1632.
5. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA*. 2023;330:512-527.
6. Mattke S, Jun H, Chen E, et al. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. *Alzheimers Res Ther*. 2023;15:128.
7. Canestaro WJ, Bateman RJ, Holtzman DM, et al. Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. *Popul Health Manag*. 2024;27:174-184.
8. Weber DM, Taylor SW, Lagier RJ, et al. Clinical utility of plasma Abeta42/40 ratio by LC-MS/MS in Alzheimer's disease assessment. *Front Neurol*. 2024;15:1364658.
9. Weber DM, Kim JC, Goldman SM, et al. New plasma LC-MS/MS assays for the quantitation of beta-amyloid peptides and identification of apolipoprotein E proteoforms for Alzheimer's disease risk assessment. *J Investig Med*. 2024;72:465-474.
10. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol*. 2024;81:255-263.
11. Jack CR, Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement*. 2024;20:5143-5169.
12. Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. *Alzheimers Res Ther*. 2022;14:26.
13. Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. *Alzheimers Dement*. 2023;19:1204-1215.
14. Meyer MR, Kirmess KM, Eastwood S, et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Abeta42/40 ratio to identify presence of brain amyloid. *Alzheimers Dement*. 2024;20:3179-3192.
15. Hu Y, Kirmess KM, Meyer MR, et al. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment. *JAMA Netw Open*. 2022;5:e228392.
16. Figdore DJ, Griswold M, Bornhorst JA, et al. Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. *Alzheimers Dement*. 2024;20:6506-6516.
17. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma Abeta42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. *Mol Neurodegener*. 2021;16:30.

18. Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease. *Nat Rev Neurol*. 2024;20:426-439.

19. Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimers Dement*. 2022;18:2669-2686.

20. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol*. 2022;21:66-77.

21. Tsoy E, La Joie R, VandeVrede L, et al. Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias. *Alzheimers Dement*. 2024;20:2089-2101.

22. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43:2412-2414.

23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12:189-198.

24. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53:695-699.

25. Duara R, Loewenstein DA, Greig M, et al. Reliability and validity of an algorithm for the diagnosis of normal cognition, mild cognitive impairment, and dementia: implications for multicenter research studies. *Am J Geriatr Psychiatry*. 2010;18:363-370.

26. Duara R, Loewenstein DA, Lizarraga G, et al. Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity. *Neuroimage Clin*. 2019;22:101800.

27. Rabe C, Bittner T, Jethwa A, et al. Clinical performance and robustness evaluation of plasma amyloid-beta(42/40) prescreening. *Alzheimers Dement*. 2023;19:1393-1402.

28. Brum WS, Cullen NC, Janelidze S, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases. *Nat Aging*. 2023;3:1079-1090.

29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. 1988;44:837-845.

30. Jansen WJ, Janssen O, Tijms BM, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. *JAMA Neurol*. 2022;79:228-243.

31. Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. *JAMA Neurol*. 2018;75:970-979.

32. Regy M, Dugravot A, Sabia S, et al. The role of dementia in the association between APOE4 and all-cause mortality: pooled analyses of two population-based cohort studies. *Lancet Healthy Longev*. 2024;5:e422-e430.

33. Fortea J, Pegueroles J, Alcolea D, et al. Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer's disease. *Nat Med*. 2024;30:2093.

34. Collij LE, Bischof GN, Altomare D, et al. Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. *J Nucl Med*. 2025;66:110-116.

35. Anderson J, Pierce C. PrecivityAD for Diagnosis of Alzheimer Disease. *Am Fam Physician*. 2022;105:79-81.

36. DeSimone JC, Wang WE, Loewenstein DA, et al. Diffusion MRI relates to plasma Abeta42/40 in PET negative participants without dementia. *Alzheimers Dement*. 2024;20:2830-2842.

570

Figure 1. Receiver operating characteristic-area under the curve (ROC-AUC) analysis for individual and combined biomarkers for prediction of PET status. Abbreviations: Aβ, beta-amyloid; *APOE4*, *APOE ε4*; AUC, area under the curve.



Figure 2. Boxplots of likelihood scores stratified by PET status for (A) ptau-217, (B) Aβ42/40, (C) Aβ42/40 + ptau-217, (D) Aβ42/40 + ptau-217 +*APOE4* carrier status, and (E) Aβ42/40 + ptau-217 +*APOE4* allele count. Orange dots represent individuals that are MCI; blue dots represent individuals that are AD. Horizontal dashed lines indicate high and low likelihood cutoffs. Results between these lines indicate neither a low nor high likelihood (ie, an indeterminate result).



Figure 3: Distribution of model results for A) the intended use population, and B) real-world clinical specimens. Orange dots represent individuals that are amyloid PET negative; blue dots represent those that are amyloid PET positive in panel A. Grey dots represent individuals whose amyloid PET status is unknown. Horizontal dashed lines indicate high and low likelihood cutoffs.



Table 1. Baseline characteristics by amyloid PET status.

Characteristic	Full Cohort [N = 215]	Aβ PET- [N=116]	Aβ PET+ [N = 99]	*P*-value
Age (years)				
Mean (SD) [N]	78.9 (8.4) [215]	78.6 (8.1) [116]	79.3 (8.8) [99]	.552
Sex				
% female [N]	56.3% [121]	53.4% [62]	59.6% [59]	.409
Ethnicity				
% Hispanic [N]	54.4% [117]	53.4% [62]	55.6% [55]	.785
Education				
Mean (SD) [N]	15.1 (3.3) [214]	15.4 (3.3) [114]	14.8 (3.2) [99]	.192
Diagnosis				
% MCI [N]	79.1% [170]	100% [116]	54.5% [54]	
% AD [N]	20.9% [45]	0% [0]	45.5% [45]	
MMSE				
%MMSE ≥ 25 [N]	74.7% [165]	94.0 [109]	57.7 [56]	*< .001*
Mean (SD) [N]	26.1 (4.3) [213]	28.1 (2.1) [116]	23.8 (5.1) [97]	
CDR				
% CDR > 0 [N]	94.4% [203]	91.4% [106]	98.0% [97]	*.040*
Plasma Aβ42/40				
Mean (SD) [N]	0.157 (0.028) [215]	0.172 (0.027) [116]	0.141 (0.018) [99]	*< .001*
Plasma Aβ42 (pg/mL)				
Mean (SD) [N]	60.4 (18.2)	65.6 (19.2) [116]	54.4 (14.8) [99]	*< .001*
Plasma Aβ40 (pg/mL)				
Mean (SD) [N]	383.2 (87.6)	380.5 (87.5) [116]	386.3 (88.2) [99]	.631
Plasma ptau-217 (pg/mL)				
Median (IQR) [N]	0.26 (0.11 - 0.54) [215]	0.12 (0.06 - 0.25) [116]	0.51 (0.32 - 0.88) [99]	*< .001*
APOE4				
% *APOE4*+ carriers [N]	38.1% [82]	21.6% [25]	57.6% [57]	
% *APOE4* allele count 1 [N]	32.6% [70]	21.6% [25]	45.5% [45]	*< .001*
% *APOE4* allele count 2 [N]	5.6% [12]	0% [0]	12.1% [12]	

Abbreviations: Aβ, beta-amyloid; AD, Alzheimer's disease; *APOE4*, *APOE* ε4; CDR, clinical dementia rating; IQR, interquartile range; MMSE, mini-mental state examination; SD, standard deviation. *P*-values show significance between Aβ PET- and Aβ PET+ groups. Not all demographic data were available for all participants; therefore, N is the number of participants where data was available.

Table 2. Model performance for prediction of amyloid PET status using a 2-cutpoint approach. Breakdown of population percentages are shown for each likelihood range (low, indeterminate, high). Sensitivities are calculated from the low likelihood cutpoint, and specificities are calculated from the high likelihood cutpoint. Accuracies are shown at the low and high likelihood cutpoints. Model predictor cutpoints represent probabilities of amyloid PET positivity.

Predictor: Two cutpoint

ptau-217	**Cutpoint**	**Aβ PET+, N [%]**	**All, N [%]**	**Sensitivity (95% CI)**	**Specificity (95% CI)**	**Accuracy, % (95% CI)**	**AUC (95% CI)**	**AIC**
Low likelihood	< 0.2490	8 [8%]	73 [34%]	92% (85% to 96%)	-	73% (66% to 78%)	0.846 (0.808 to 0.905)	262.7
Indeterminate likelihood	0.2490 to 0.7554	49 [50%]	91 [42%]	-	-	-		
High likelihood	> 0.7554	42 [42%]	51 [24%]		92% (86% to 96%)	69% (63% to 75%)		

Aβ42/40	**Cutpoint**	**Aβ PET+, N [%]**	**All, N [%]**	**Sensitivity (95% CI)**	**Specificity (95% CI)**	**Accuracy, % (95% CI)**	**AUC (95% CI)**	**AIC**
Low likelihood	< 0.3925	9 [9%]	95 [44%]	91% (84% to 95%)	-	82% (76% to 86%)	0.851 (0.796 to 0.905)	255.6
Indeterminate likelihood	0.3925 to 0.7236	53 [74%]	72 [34%]	-	-	-		
High likelihood	> 0.7236	37 [37%]	48 [22%]		91% (84% to 95%)	66% (60% to 72%)		

Model 1: pTau217 + Aβ42/40	**Cutpoint**	**Aβ PET+, N [%]**	**All, N [%]**	**Sensitivity (95% CI)**	**Specificity (95% CI)**	**Accuracy, % (95% CI)**	**AUC (95% CI)**	**AIC**
Low likelihood	< 0.3254	9 [9%]	97 [45%]	91% (84% to 95%)	-	83% (77% to 87%)	0.929 (0.894 to 0.963)	194.6
Indeterminate likelihood	0.3254 to 0.6460	16 [16%]	33 [15%]	-	-	-		
High likelihood	> 0.6460	74 [75%]	85 [40%]		91% (84% to 95%)	83% (78% to 88%)		

Model 2: pTau217 + Aβ42/40 + *APOE4* carrier status	**Cutpoint**	**Aβ PET+, N [%]**	**All, N [%]**	**Sensitivity (95% CI)**	**Specificity (95% CI)**	**Accuracy, % (95% CI)**	**AUC (95% CI)**	**AIC**
Low likelihood	<0.3709	9 [9%]	101 [47%]	91% (84% to 95%)	-	85% (79% to 89%)	0.938 (0.906 to 0.969)	189.2
Indeterminate likelihood	0.3709 to 0.5626	9 [9%]	22 [10%]	-	-	-		
High likelihood	>0.5626	81 [82%]	92 [43%]		91% (84% to 95%)	86% (81% to 90%)		

Model 3: pTau217 + Aβ42/40 + *APOE4* allele count	**Cutpoint**	**Aβ PET+, N [%]**	**All, N [%]**	**Sensitivity (95% CI)**	**Specificity (95% CI)**	**Accuracy, % (95% CI)**	**AUC (95% CI)**	**AIC**
Low likelihood	< 0.3714	9 [9%]	101 [47%]	91% (84% to 95%)	-	85% (79% to 89%)	0.942 (0.912 to 0.972)	186.6
Indeterminate likelihood	0.3714 to 0.5375	8 [8%]	21 [10%]	-	-	-		
High likelihood	> 0.5375	82 [83%]	93 [43%]		91% (84% to 95%)	87% (82% to 91%)		

Abbreviations: Aβ, beta-amyloid; AIC, Akaike Information Criterion; *APOE4*, *APOE* ε4; AUC, area under the curve; CI, confidence interval; PET, positron emission tomography

Table 3. Positive predictive values (PPV) and negative predictive values (NPV) calculated for the combination of predictors without and with *APOE* ε4 (*APOE4*) allele count based on observed prevalence of amyloid positivity in the intended use study population and expected prevalence in different population settings.

Predictor	**ptau-217 + Aβ42/40**		**ptau-217 + Aβ42/40 +*APOE4* allele count**	
Prevalence	**PPV (95% CI)**	**NPV (95% CI)**	**PPV (95% CI)**	**NPV (95% CI)**
20%, as expected in a primary care setting	66% (54% to 79%)	97% (95% to 98%)	68% (56% to 80%)	97% (95% to 99%)
46%, observed study prevalence	87% (78% to 93%)	91% (83% to 95%)	88% (80% to 93%)	91% (84% to 95%)
50%, as expected in MCI population	89% (82% to 94%)	89% (82% to 94%)	90% (84% to 96%)	90% (84% to 96%)
65%, as expected in a general neurology setting	93% (90% to 97%)	82% (72% to 90%)	94% (91% to 97%)	82% (73% to 90%)
80%, as expected in a memory care setting	97% (95% to 98%)	68% (56% to 81%)	97% (95% to 98%)	69% (57% to 82%)

Table 4. Proposed linear predictor cutpoints for clinical decision making

Probability of PET positivity range	Interpretation	Intended use population *N (*% of cohort)	PET positivity *N* (%)	MCI, *N* (%)	AD, *N* (%)	*APOE4+* carriers, *N* (%)	Real world, *N* (% of cohort)	Real world, projections of PET positivity, *N (%)*[a]	Follow-up evaluation and management considerations
< 0.3714	Low likelihood	101 (47.0%)	9 (9.0%)	101 (100%)	0 (0%)	16 (15.8%)	2,204 (50.9%)	198 (9.0%)	Consider non-AD etiology
0.3714 to 0.5375	Indeterminate likelihood	21 (9.8%)	8 (38.1%)	18 (85.7%)	3 (14.3%)	10 (47.6%)	300 (6.9%)	114 (38.0%)	Consider results within context of full differential; refer to a neurologist
> 0.5375	High likelihood	93 (43.3%)	82 (88.2%)	51 (54.8%)	42 (45.2%)	56 (60.2%)	1,822 (42.1%)	1607 (88.2%)	Consider results within context of full differential; refer to a neurologist; AD etiology likely; potential candidate for anti-amyloid therapy
All	All	215 (100%)	99 (46.0%)	170 (79.1%)	45 (20.9%)	82 (38.1%)	4,326 (100%)	1919 (44.4%)	

Abbreviations: AD, Alzheimer's disease; *APOE4*, *APOE* ε4; MCI, mild cognitive impairment; PET, positron emission tomography.
[a] Real world projections of PET positivity are based one percent PET positivity in the intended use population cohort.